(Q44824156)

English

Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.

scientific article published in May 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15121305%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15121305%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

0 references

cysteine peptidase B (CPB)

1 reference

5 February 2019

cysteine peptidase A (CPA)

1 reference

5 February 2019

cysteine peptidase A (CPA)

0 references

Leishmania major

1 reference

based on heuristic

inferred from title

0 references

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15121305%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15121305%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Azita Zadeh-Vakili

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15121305%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Yasaman Taslimi

3

object named as

Yasaman Taslimi

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15121305%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Fatemeh Doustdari

4

object named as

Fatemeh Doustdari

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15121305%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Ali-Hatef Salmanian

5

object named as

Ali-Hatef Salmanian

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15121305%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

language of work or name

0 references

publication date

1 May 2004

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15121305%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15121305%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15121305%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

15-16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15121305%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1930-1940

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15121305%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Leishmaniasis: current status of vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.014

7 January 2021

Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.014

7 January 2021

Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.014

7 January 2021

The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.014

7 January 2021

Leishmania Cysteine Proteinases: From Gene to Subunit Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.014

7 January 2021

Antigen presentation by Leishmania mexicana-infected macrophages: activation of helper T cells specific for amastigote cysteine proteinases requires intracellular killing of the parasites.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.014

7 January 2021

Identification of Leishmania major cysteine proteinases as targets of the immune response in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.014

7 January 2021

Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing CD8(+) T lymphocyte activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.014

7 January 2021

A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.014

7 January 2021

Genetic immunization of BALB/c mice with a plasmid bearing the gene coding for a hybrid merozoite surface protein 1-hepatitis B virus surface protein fusion protects mice against lethal Plasmodium chabaudi chabaudi PC1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.014

7 January 2021

Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.014

7 January 2021

Leishmania major: comparison of the cathepsin L- and B-like cysteine protease genes with those of other trypanosomatids

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.014

7 January 2021

Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.014

7 January 2021

Leishmania major: molecular cloning, sequencing, and expression of the heat shock protein 60 gene reveals unique carboxy terminal peptide sequences

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.014

7 January 2021

Imidazole-SDS-Zn reverse staining of proteins in gels containing or not SDS and microsequence of individual unmodified electroblotted proteins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.014

7 January 2021

On the post-translational modifications at the C-terminal domain of the major cysteine proteinase (cruzipain) from Trypanosoma cruzi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.014

7 January 2021

Roles of cysteine proteinases of trypanosomes and Leishmania in host-parasite interactions.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.014

7 January 2021

The Leishmania mexicana cysteine protease, CPB2.8, induces potent Th2 responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.014

7 January 2021

Vaccination of BALB/c mice with Leishmania major amastigote-specific cysteine proteinase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.014

7 January 2021

Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.014

7 January 2021

Long-term protection of mice against Leishmania major with a synthetic peptide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.014

7 January 2021

Biochemical analysis and immunogenicity of Leishmania major amastigote fractions in cutaneous leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.014

7 January 2021

Th1 cell development induced by cysteine proteinases A and B in localized cutaneous leishmaniasis due to Leishmania guyanensis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.014

7 January 2021

Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.014

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization of an antigen from Leishmania amazonensis amastigotes able to elicit protective responses in a murine model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.014

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2003.11.014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15121305%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15121305%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44824156&oldid=1743158496"